
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is structured to mirror the performance of the Dorsey Wright Healthcare Technical Leaders Index. This exchange-traded fund typically allocates a minimum of 90% of its total assets to the equities found within this benchmark index. The Index itself is specifically engineered to identify healthcare companies that demonstrate strong "relative strength," which indicates significant momentum. It consists of no fewer than 30 individual securities selected from the broader NASDAQ US Benchmark Index. "Relative strength" refers to the process of…
Is PTH's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D.

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), a passively managed exchange traded fund launched on October 12, 2006.

HONG KONG, Aug 31, 2026 - (ACN Newswire) - Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital StructureOn August 2

TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of the ASBMR 2026 Annual Meeting.